Press Releases Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-09 EST			5-day change	1st Jan Change
119.36 ^USD	-1.51%		-3.67%	+29.22%

12-08	Assembly Biosciences Reports Positive Interim Results from Phase 1B Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates Abi-1179 and Abi-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirms Genital Herpes	CI
12-08	Gilead Sciences' Kite Says Yescarta Shows 'Consistent' Benefits in Large B-cell Lymphoma	MT

Press Releases

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer	12-09	BU
Gilead Sciences : Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025	12-07	PU
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025	12-07	BU
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025	12-06	BU
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma	12-06	BU
Sprint Bioscience (Q3 review) - Gilead deal a strong confirmation	12-05	AQ
National AIDS Memorial Marks World AIDS Day with Two Signature Events Highlighting the Power of Communities to Shape Progress in the Fight Against HIV/AIDS and Advance Health and Social Justice	12-02	AQ
Gilead Foundation Commits Over $3 Million to Address Food Insecurity	11-24	BU
Sprint Bioscience sells the TREX1 program to Gilead	11-24	AQ
New Twice-Yearly HIV Jab Might Be Too Pricey for Namibia, Says Former Minister	11-24	AQ
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs	11-20	PR
Eswatini is the first African country to get twice-yearly HIV prevention shot	11-18	AQ
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa	11-18	BU
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial	11-13	BU
Gilead Provides Update on Phase 3 ASCENT-07 Study	11-07	BU
Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression	11-07	BU
Gilead Sciences to Present at Upcoming Investor Conferences	11-04	BU
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025	11-03	BU
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)	10-31	BU
Gilead Sciences : Third Quarter 2025 Resource Book	10-30	PU
Gilead Sciences : Third Quarter 2025 Summary of Remarks	10-30	PU
Gilead Sciences : Third Quarter 2025 Supplementary Information	10-30	PU
Gilead: Q3 Earnings Snapshot	10-30	AQ
Gilead Sciences Announces Third Quarter 2025 Financial Results	10-30	BU
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi in Primary Biliary Cholangitis and Investigational Bulevirtide in Chronic Hepatitis Delta	10-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Time To Grow PFL Fanbase, Revenue: CEO John Martin

July 11, 2025 at 04:09 am